Replimune logo

ReplimuneNASDAQ: REPL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 July 2018

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$701.96 M
-57%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector
-55%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:59:44 GMT
$10.26-$1.14(-10.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

REPL Latest News

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
globenewswire.com09 November 2024 Sentiment: POSITIVE

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com08 November 2024 Sentiment: POSITIVE

WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
globenewswire.com15 September 2024 Sentiment: POSITIVE

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
globenewswire.com13 August 2024 Sentiment: POSITIVE

Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma

Replimune to Present at Two Upcoming Investor Conferences
globenewswire.com30 July 2024 Sentiment: POSITIVE

WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences:

Replimune (REPL) Gains on Positive Data From Melanoma Study
zacks.com07 June 2024 Sentiment: POSITIVE

Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
globenewswire.com07 June 2024 Sentiment: POSITIVE

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET.

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
globenewswire.com06 June 2024 Sentiment: POSITIVE

Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass.

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
Zacks Investment Research11 March 2024 Sentiment: NEUTRAL

The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What type of business is Replimune?

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

What sector is Replimune in?

Replimune is in the Healthcare sector

What industry is Replimune in?

Replimune is in the Biotechnology industry

What country is Replimune from?

Replimune is headquartered in United States

When did Replimune go public?

Replimune initial public offering (IPO) was on 20 July 2018

What is Replimune website?

https://www.replimune.com

Is Replimune in the S&P 500?

No, Replimune is not included in the S&P 500 index

Is Replimune in the NASDAQ 100?

No, Replimune is not included in the NASDAQ 100 index

Is Replimune in the Dow Jones?

No, Replimune is not included in the Dow Jones index

When was Replimune the previous earnings report?

No data

When does Replimune earnings report?

The next expected earnings date for Replimune is 07 February 2025